Sanofi to acquire biotechnology firm Synthorx for $2.5 billion
Category: #health  By Saipriya Iyer  Date: 2019-12-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi to acquire biotechnology firm Synthorx for $2.5 billion

Sanofi, a renowned France based multinational pharmaceutical company, reportedly announced that it would be acquiring California based biotechnology firm, Synthorx, for $2.5 billion. Sanofi offered to purchase all outstanding shares of Synthorx in cash for $68 per share, or a premium of 172% to Synthorx’s Dec. 6, 2019 closing price.

Paul Hudson, Chief Executive, Sanofi, reportedly stated that the acquisition fits ideally with the company’s strategy to build high-quality assets and to lead innovation. Hudson further adds that the deal is aligned with the company’s goal to build their oncology franchise with practice changing medicines and new combinations.

As stated by the company’s website, Synthorx is a clinical-stage biotech firm focusing on therapies for people diagnosed with auto immune disorders and cancer. It recorded a net loss of $56.6 million in 2018.

The acquisition is expected to be completed in the first quarter of 2020.

A broad strategy review was conducted by Sanofi under Hudson. Hudson had given initial pointers as to which business the company would focus on during investor day held in Cambridge, Massachusetts on December 10. Furthermore, Hudson also stated that significant changes are being made in the company.

As a precursor to its new growth strategy, Sanofi sold its Seprafilm unit to Baxter International, a medical supply company, for $350 million in cash.

About Sanofi:

Sanofi is a renowned pharmaceutical company headquartered in Paris, France. The company engages in the marketing and manufacturing, research and development of pharmaceutical drugs, it also develops medications over the counter. It covers seven major therapeutic areas like internal medicine, central nervous system, diabetes, oncology, vaccines, thrombosis and cardiovascular.

About Synthorx:

Synthorx is a renowned biotech firm focusing on improving lives of people diagnosed with autoimmune and cancer disorders. The firms leading product, THOR-707, a variation of IL-2 has been developed in multiple tumor types as a single agent combined with an immune checkpoint inhibitor.
 

Source credit: https://www.reuters.com/article/us-sanofi-m-a-synthorx/frances-sanofi-to-buy-biotech-firm-synthorx-for-2-5-billion-idUSKBN1YD0FW



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

CTI-Medidata partner to adopt Remote Source Review in clinical trials
CTI-Medidata partner to adopt Remote Source Review in clinical trials
By Saipriya Iyer

CTI Clinical Trial and Consulting Services will reportedly adopt Remote Source Review of Medidata. Medidata is the end-to-end solutions provider to support the clinical trials. This contract research organization will ...

NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
By Saipriya Iyer

Nizam’s Institute of Medical Science (NIMS) has recently commenced the enrollment of subjects for its Phase 1 clinical trials of the COVID-19 vaccine. It is the 1st indigenous coronavirus vaccine candidate develo...

Walmart to compete Amazon Prime with new subscription service, Walmart
Walmart to compete Amazon Prime with new subscription service, Walmart
By Saipriya Iyer

U.S retail giant, Walmart Inc. has recently joined the race against Amazon with its latest subscription service, Walmart+. Similar to Amazon Prime, the new subscription service will endow Walmart customers wi...